mz gets to work

Phosphagenics to Host Investor Call on Wednesday, April 2nd at 4:00pm EDT (USA)

Management to Detail the Commercialization of High Value Pain Products including Oxycodone using its TPM® Topical Drug Delivery Technology

PR Newswire
MELBOURNE, Australia, March 26, 2014

MELBOURNE, Australia, March 26, 2014 /PRNewswire/ --

Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY)
("Phosphagenics" or "the Company") announced today that management will host an investor conference call and webcast to discuss the commercial opportunities arising from a range of innovative analgesic products emerging from the Company's patented TPM® drug delivery technology. The Company will describe how TPM® is enabling it to establish a unique competitive position in the transdermal and topical delivery of diverse analgesics, including oxymorphone and oxycodone. The Company will review current success stories, ongoing and future development plans, and the commercial opportunity for unique and innovative products that overcome the limitations of analgesics currently on market.

The Company's CEO, Harry Rosen, CSO, Paul Gavin, General Counsel, Jason Rosen, and VP of Business Development, Alex Stojanovic, will host the call with investors and analysts...

"We believe that our products are novel and differentiated offerings for the multi-billion dollar pain therapeutics markets worldwide," began Harry Rosen, CEO of Phosphagenics Limited. "We are especially excited about opportunities to deploy our patented drug delivery system to improve the effectiveness of many analgesics. Phase 1 data on our TPM®/Oxymorphone and TPM®/Oxycodone patches have delivered outstanding results, including the delivery of therapeutic amounts of drug at a constant rate for the duration of patch application, rapid elimination after patch removal and minimal skin irritation at the application site. We are the first company in the world that has been able to deliver such levels of these molecules transdermally, a result that has promoted early commercial discussions with potential licensees. This is an exciting time for Phosphagenics, as we are now preparing for an IND in the US and moving toward initiation of pivotal Phase 2/3 trials."

About Phosphagenics

Phosphagenics Limited is a biotechnology company that is commercializing various products within the pharmaceutical, cosmetics, and animal health sectors, using its proprietary drug delivery system called TPM® (Targeted Penetration Matrix). TPM® is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.


Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).


http://www.reuters.com/article/2014/03/26/phosphagenics-cnfcall-idUSnPn3Sts4p+90+PRN20140326

(Webcast and replay access details can be found at the link above)